In addition, RECQL4 is considered a potential molecular target for cancer therapy given that it correlates with a stem cell phenotype,6,7 and its overexpression has been observed to confer resistance to chemotherapy regimens in preclinical settings, including glioma.8–10. This evidence concerns the gene RECQL4 and cancer.